Abstract:Rationale: As a cancer, Glioblastoma (GBM) is a highly lethal and difficult-to-treat. With the aim of improving therapies to GBM, we developed novel and target-specific theranostic nanoparticles (TNPs) that can be selectively cleaved by cathepsin B (Cat B) to release the potent toxin monomethyl auristatin E (MMAE). Methods: We synthesized TNPs composed of a ferumoxytol-based nanoparticle carrier and a peptide prodrug with a Cat-B-responsive linker and the tubulin inhibitor MMAE. We hypothesized that intratumoral Cat B can cleave our TNPs and release MMAE to kill GBM cells. The ferumoxytol core enables in vivo drug tracking with magnetic resonance imaging (MRI). We incubated U87-MG GBM cells with TNPs or ferumoxytol and evaluated the TNP content in the cells with transmission electron microscopy and Prussian blue staining. In addition, we stereotaxically implanted 6- to 8-week-old nude mice with U87-MG with U87-MG GBM cells that express a fusion protein of Green Fluorescence Protein and firefly Luciferase (U87-MG/GFP-fLuc). We then treated the animals with an intravenous dose of TNPs (25 mg/kg of ferumoxytol, 0.3 mg/kg of MMAE) or control. We also evaluated the combination of TNP treatment with radiation therapy. We performed MRI before and after TNP injection. We compared the results for tumor and normal brain tissue between the TNP and control groups. We also monitored tumor growth for a period of 21 days. Results: We successfully synthesized TNPs with a hydrodynamic size of 41 ± 5 nm and a zeta potential of 6 ± 3 mV. TNP-treated cells demonstrated a significantly higher iron content than ferumoxytol-treated cells (98 ± 1% vs. 3 ± 1% of cells were iron-positive, respectively). We also found significantly fewer live attached cells in the TNP-treated group (3.8 ± 2.0 px2) than in the ferumoxytol-treated group (80.0 ± 14.5 px2, p < 0001). In vivo MRI studies demonstrated a decline in the tumor signal after TNP (T2= 28 ms) but not control (T2= 32 ms) injections. When TNP injection was combined with radiation therapy, the tumor signals dropped further (T2 = 24 ms). The combination therapy of radiation therapy and TNPs extended the median survival from 14.5 days for the control group to 45 days for the combination therapy group. Conclusion: The new cleavable TNPs reported in this work accumulate in GBM, cause tumor cell death, and have synergistic effects with radiation therapy.

In Vivo MR Imaging of Glioma Recruitment of Adoptive T-Cells Labeled with NaGdF4 -TAT Nanoprobes.

In Vivo Magnetic Resonance Imaging of CD8+ T Lymphocytes Recruiting to Glioblastoma in Mice

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma

Non-invasive Monitoring of the Kinetic Infiltration and Therapeutic Efficacy of Nanoparticle-Labeled Chimeric Antigen Receptor T Cells in Glioblastoma Via 7.0-Tesla Magnetic Resonance Imaging

MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma

Nagdf4 Nanoparticle-Based Molecular Probes for Magnetic Resonance Imaging of Intraperitoneal Tumor Xenografts in Vivo

Nanoprobes Visualizing Gliomas by Crossing the Blood Brain Tumor Barrier

Metabolic Radiolabeling and in Vivo PET Imaging of Cytotoxic T Lymphocytes to Guide Combination Adoptive Cell Transfer Cancer Therapy

In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI

In Vivo Imaging of T Cells Loaded with Gold Nanoparticles: a Pilot Study

In Vivo Tracking of Superparamagnetic Iron Oxide Nanoparticle-Labeled Mesenchymal Stem Cell Tropism to Malignant Gliomas Using Magnetic Resonance Imaging. Laboratory Investigation.

NaGdF4-based Magnetic Resonance Nanoprobes for Qualitative Inflammation Imaging in Glioma: Hot or Cold?

A Smart Responsive Fluorescence‐MR Nanoprobe for Monitoring Tumor Response to Immunotherapy

Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models

Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma.

Dual-targeting and Excretable Ultrasmall SPIONs for T1-weighted Positive MR Imaging of Intracranial Glioblastoma Cells by Targeting the Lipoprotein Receptor-Related Protein

Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy

High-efficiency magnetophoretic labelling of adoptively-transferred T cells for longitudinal in vivo Magnetic Particle Imaging

Targeted Delivery of a Γ-Glutamyl Transpeptidase Activatable Near-Infrared-Fluorescent Probe for Selective Cancer Imaging

Efficacy of Antiangiogenic Targeted Immunotoxin DTAT and DTATEGF Against Glioblastoma Multiforme.

Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene